U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H17NO2
Molecular Weight 159.2264
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREGABALIN

SMILES

CC(C)C[C@@]([H])(CC(=O)O)CN

InChI

InChIKey=AYXYPKUFHZROOJ-ZETCQYMHSA-N
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H17NO2
Molecular Weight 159.2264
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17126531

Pregabalin, marketed under the brand name Lyrica among others. LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) Postherpetic neuralgia (PHN); Adjunctive therapy for adult patients with partial onset seizures; Fibromyalgia; Neuropathic pain associated with spinal cord injury. It has been shown the clinical effects of pregabalin are likely due to direct and selective interactions with α(2)δ-1 and α(2)δ-2 subunits of voltage-gated calcium channels. While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid (GABA), it does not bind directly to GABAA, GABAB, or benzodiazepine receptors, does not augment GABAA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in mouse, rat, monkey. Human data not available

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

1.10436483E12
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

1.10436483E12
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

1.10436483E12
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

1.10436483E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4568.68 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREGABALIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29831.454 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREGABALIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
unknown, oral
PREGABALIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Other AEs: Vision blurred, Nausea...
Other AEs:
Vision blurred (moderate, 1 patient)
Nausea (moderate, 1 patient)
Dizziness (mild, 4 patients)
Dysarthria (moderate, 1 patient)
Headache (mild, 2 patients)
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 53.91 years
n = 22
Health Status: unhealthy
Condition: Essential Tremor
Age Group: 53.91 years
Sex: M+F
Population Size: 22
Sources:
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Disc. AE: Dizziness, Somnolence...
AEs leading to
discontinuation/dose reduction:
Dizziness (3.47%)
Somnolence (2.76%)
Asthenia (0.82%)
Confusion (0.72%)
Peripheral edema (0.61%)
Headache (1.12%)
Amblyopia (0.82%)
Dry mouth (0.72%)
Nausea (0.72%)
Infection (0.41%)
Ataxia (0.41%)
Neuropathy (0.41%)
Tremor (0.41%)
Constipation (0.31%)
Diarrhea (0.31%)
Incoordination (0.31%)
Abnormal thinking (0.31%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache mild, 2 patients
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Dizziness mild, 4 patients
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Dysarthria moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Nausea moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Vision blurred moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Abnormal thinking 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Constipation 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Diarrhea 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Incoordination 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Ataxia 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Infection 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Neuropathy 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Tremor 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Peripheral edema 0.61%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Confusion 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Dry mouth 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Nausea 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Amblyopia 0.82%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Asthenia 0.82%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Headache 1.12%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Somnolence 2.76%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Dizziness 3.47%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
The new generation of GABA enhancers. Potential in the treatment of epilepsy.
2001
Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder).
2001
Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices.
2001 Aug
Pregabalin enhances nonrapid eye movement sleep.
2001 Dec
Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity.
2001 Jan
Brain microdialysis and PK/PD correlation of pregabalin in rats.
2001 Jan-Jun
Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma-aminobutyric acid derivatives.
2001 Nov
Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.
2002
New single-isomer compounds on the horizon.
2002 Apr
Gateways to Clinical Trials.
2002 Apr
Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.
2002 Feb
Gateways to Clinical Trials. June 2002.
2002 Jun
Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia.
2002 Nov
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
2002 Sep
Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.
2002 Sep
Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.
2002 Sep 1
The role of GABA in the pathophysiology and treatment of anxiety disorders.
2003
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
2003 Apr 22
Gateways to clinical trials.
2003 Dec
Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells.
2003 Feb 7
Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat.
2003 Jul
Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations.
2003 Jul
GABA-ergic drugs: exit stage left, enter stage right.
2003 Jun
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
2003 Jun
Gateways to clinical trials. March 2003.
2003 Mar
Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.
2003 Sep
Pregabalin: in the treatment of painful diabetic peripheral neuropathy.
2004
[New molecular targets in pharmacological treatment of anxiety disorders].
2004
Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.
2004
Selecting pharmacotherapy for generalized anxiety disorder.
2004
Pregabalin as adjunctive therapy for partial seizures.
2004
Pregabalin pharmacology and its relevance to clinical practice.
2004
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.
2004 Aug
A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats.
2004 Aug 4
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
2004 Dec 14
Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.
2004 Jan
Pharmacologic management part 1: better-studied neuropathic pain diseases.
2004 Mar
American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
2004 May
[How neuropathic is sciatica? The mixed pain concept].
2004 May
[New options in the treatment of various forms of diabetic neuropathy].
2004 May 20
Gateways to clinical trials.
2004 Nov
Gateways to clinical trials.
2004 Oct
Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines.
2004 Oct
Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection.
2004 Oct 25
Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro.
2004 Sep
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
2004 Sep 28
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
2004 Sep-Oct
The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003.
2004 Summer
Pregabalin: in the treatment of postherpetic neuralgia.
2005
Patents

Sample Use Guides

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy: The maximum recommended dose is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Postherpetic Neuralgia: The recommended dose is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Adjunctive Therapy for Adult Patients with Partial Onset Seizures: LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Management of Fibromyalgia: The recommended dose is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Neuropathic Pain Associated with Spinal Cord Injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Pregabalin antagonizes the neurotoxic effects of copper
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:06:52 UTC 2021
Edited
by admin
on Fri Jun 25 21:06:52 UTC 2021
Record UNII
55JG375S6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREGABALIN
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-759256
Code English
PREGABALIN [ORANGE BOOK]
Common Name English
(S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID
Systematic Name English
PREGABALIN [USAN]
Common Name English
PREGABALIN [VANDF]
Common Name English
PREGABALIN [JAN]
Common Name English
PREGABALIN SANDOZ
Brand Name English
LYRICA CR
Brand Name English
PREGABALIN [MART.]
Common Name English
VRONOGABIC
Common Name English
PREGABALIN [WHO-DD]
Common Name English
PREGABALIN MYLAN
Brand Name English
PREGABALIN [INN]
Common Name English
CI-1008
Code English
PREGABALIN [HSDB]
Common Name English
PREGABALIN ZENTIVA
Brand Name English
LYRICA
Brand Name English
PREGABALIN [MI]
Common Name English
PREGABALIN MYLAN PHARMA
Brand Name English
PD-144723
Code English
PREGABALIN [USP-RS]
Common Name English
PREGABALIN SANDOZ GMBH
Brand Name English
PREGABALIN [USP MONOGRAPH]
Common Name English
YNP-1807
Code English
PREGABALIN [EP MONOGRAPH]
Common Name English
PREGABALIN [EMA EPAR]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS PREGABALIN PFIZER (AUTHORIZED: NEURALGIA)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS PREGABALIN ZENTIVA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
WHO-ATC N03AX16
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
WHO-VATC QN03AX16
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS PREGABALIN SANDOZ GMBH (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
NCI_THESAURUS C264
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
LIVERTOX 796
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS PREGABALIN MYLAN PHARMA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: ANXIETY DISORDERS)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: NEURALGIA)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS PREGABALIN MYLAN (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
NCI_THESAURUS C2198
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
DEA NO. 2782
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS PREGABALIN SANDOZ (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
Code System Code Type Description
DRUG CENTRAL
2255
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
FDA UNII
55JG375S6M
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
NCI_THESAURUS
C64625
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
LACTMED
Pregabalin
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
EVMPD
SUB10023MIG
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
IUPHAR
5484
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
CAS
148553-50-8
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
MESH
C080245
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
HSDB
7530
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
DRUG BANK
DB00230
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
ChEMBL
CHEMBL1059
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
EPA CompTox
148553-50-8
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
RXCUI
187832
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY RxNorm
PUBCHEM
5486971
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
MERCK INDEX
M9113
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY Merck Index
INN
7643
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
USP_CATALOG
1559618
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
PREGABALIN
Created by admin on Fri Jun 25 21:06:52 UTC 2021 , Edited by admin on Fri Jun 25 21:06:52 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
URINE
TARGET->LIGAND
INNOVATOR->PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
ENANTIOMERIC PURITY/HPLC
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC